BB's Stock Haven

[k124Inv]

ARTH ~ ARFRAMINGHAM, MA--(Marketwired - Oct 31, 2016) - Arch Therapeutics, Inc. ( OTCQB : ARTH ) ("Arch" or the "Company"), developer of devices for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, reports additional positive data in its recently completed single-center, randomized, single-blind prospective clinical study (NCT 02704104) of the AC5 Topical Hemostatic Device™ ("AC5™") in skin lesion patients with bleeding wounds. On August 15, 2016, the Company reported top-line data from the clinical study that indicated that AC5 was safe and that it reduced time to hemostasis in wounds versus controls."


~ Money Maker

https://finance.yahoo.com/news/arch-therapeutics-reports-ac5-topical-115700428.html